FDA Approves Drug Combination for Treating BRAF-positive Anaplastic Thyroid Cancer
May 7th 2018The FDA has approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic.
Read More
FDA OKs Therapy for BRAF Mutation-Positive Anaplastic Thyroid Cancer
May 7th 2018The FDA approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic.
Read More